PharmaResearch to Enhance REJURAN Cosmetics Presence in the Americas with CG USA Acquisition

PharmaResearch Expands REJURAN Cosmetics in the Americas

PharmaResearch, a South Korean company recognized for its advancements in regenerative medicine, is making significant strides to fortify its presence in the beauty market across North and South America. The company's recent agreement to acquire Cosmetic Group USA (CG USA) is a strategic move aimed at enhancing local manufacturing capabilities and accelerating the expansion of its REJURAN Cosmetics line.

On June 30, 2026, PharmaResearch announced its plans to bring CG USA into its fold. This acquisition comes in response to the growing consumer demand for REJURAN Cosmetics, which has been notably propelled by successful launches in Sephora and on Amazon. Previously, the U.S. market sourced these products from Korean facilities; the acquisition seeks to establish a robust local production base.

Local Manufacturing and Enhanced Logistics

CG USA, headquartered in California, is a well-regarded manufacturer in the cosmetics industry with comprehensive capabilities that span from product planning and formula development to manufacturing and packaging. Their facility is FDA-registered and adheres to the stringent standards of current good manufacturing practices (cGMP), ensuring that the quality of products remains uncompromised.

This acquisition is poised to streamline PharmaResearch’s supply chain, allowing for improved efficiency and responsiveness to the market's needs. Ji Hoon Sohn, PharmaResearch's CEO, emphasized that this acquisition will not only stabilize supply chains in North America but also prepare the company for future growth across Canada and other regions in the Americas.

Accelerating Localized Strategies

The strategic acquisition aligns seamlessly with PharmaResearch's localization strategy. By securing CG USA, the company aims to enhance its capability to distribute and produce REJURAN Cosmetics effectively, thereby meeting the increasing demands of the North American market.

This plan includes an imminent launch into the Canadian market within the latter half of the year, further solidifying the brand's footprint in this region. REJURAN represents PharmaResearch's premium dermal cosmetics line, showcasing innovative beauty products derived from regenerative medicine technologies.

Brand Development and Future Prospects

REJURAN Cosmetics utilizes DOT™ c-PDRN®, a patented ingredient known for its cosmetic-grade properties. As the brand gears up for its introduction into Canadian and broader North American markets, this acquisition is expected to provide a significant boost to its competitive edge, positioning PharmaResearch as a leader in the industry.

A representative from CG USA expressed excitement about the partnership, citing the merger of CG USA’s manufacturing acumen with PharmaResearch’s expertise as a recipe for success. This sentiment is shared by both parties, highlighting an optimistic outlook for the brand's growth trajectory.

Conclusion

As PharmaResearch embarks on this new venture, the potential for innovation and growth in the cosmetics sector looks promising. With CG USA's local production capabilities now in their arsenal, PharmaResearch is set to redefine its operational approach in the Americas. This move not only reflects a commitment to localize production but also to expand the reach of REJURAN Cosmetics, ultimately enhancing customer experience and satisfaction across the region.